FN
Publications
246
Views
123,242
Downloads
20,272
Supervised works
6
Items per page
1 - 246 of 246
Title Published in Access level OA Policy Year Views Downloads
A global research priority agenda to advance public health responses to fatty liver diseaseJournal of hepatology
accessLevelPublic
2023 75 70
ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistanceScientific reports
accessLevelPublic
2023 141 50
HCV disease burden and population segments in SwitzerlandLiver international
accessLevelPublic
2022 189 94
Maladies infectieusesRevue médicale suisse
accessLevelPublic
2021 337 89
The never-ending debate about conflict of interests'Liver international
accessLevelPublic
2021 148 43
NAFLD and MAFLD as emerging causes of HCC: a populational studyJHEP Reports : Innovation in hepathology
accessLevelPublic
2021 260 152
Endpoints and New Options for Treatment of Chronic Hepatitis DHepatology
accessLevelPublic
2021 104 90
Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in SwitzerlandSwiss Medical Weekly
accessLevelPublic
2021 188 75
Recommandations pour le suivi des patients atteints d'hépatite C guérieSwiss Medical Forum
accessLevelPublic
2021 207 131
HDV pathogenesis: unravelling ariadne's threadViruses
accessLevelPublic
2021 181 93
Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapyJHEP Reports : Innovation in Hepatology
accessLevelPublic
2021 251 109
Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/PibrentasvirInfectious Diseases and Therapy
accessLevelPublic
2021 201 69
Residual risk of liver disease after hepatitis C virus eradicationJournal of Hepatology
accessLevelRestricted
2021 170 0
MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspectiveAlimentary Pharmacology and Therapeutics
accessLevelRestricted
2021 214 0
The case for simplifying and using absolute targets for viral hepatitis elimination goalsJournal of Viral Hepatitis
accessLevelRestricted
2021 181 0
Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysisPeerJ
accessLevelPublic
2021 296 73
The changing context of hepatitis DJournal of Hepatology
accessLevelRestricted
2021 184 0
Mir-21 Suppression Promotes Mouse HepatocarcinogenesisCancers
accessLevelPublic
2021 203 339
Hepatitis C virus: current steps toward elimination in Germany and barriers to reaching the 2030 goalHealth science reports
accessLevelPublic
2021 227 87
EASL recommendations on treatment of hepatitis C: final update of the seriesJournal of Hepatology
accessLevelRestricted
2020 238 0
Buyers' club : une alternative pour l'accès au traitement ?Revue médicale suisse
accessLevelPublic
2020 364 158
A letter of solidarity during the COVID-19 pandemicLiver International
accessLevelPublic
2020 144 67
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysisJournal of Hepatology
accessLevelPublic
2020 220 163
Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studiesJournal of Hepatology
accessLevelRestricted
2020 277 1
Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma"Journal of Hepatology
accessLevelPublic
2020 198 105
SARS-CoV-2 and liver damage: a possible pathogenetic linkHepatobiliary Surgery and Nutrition
accessLevelPublic
2020 196 95
Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?Swiss Medical Weekly
accessLevelPublic
2020 314 144
Securing sustainable funding for viral hepatitis elimination plansLiver International
accessLevelRestricted
2020 296 0
Natural history of NASH and HCCLiver International
accessLevelRestricted
2020 301 1
The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomesBMC Medical Education
accessLevelPublic
2020 255 224
All-Cause mortality and causes of death in the Swiss Hepatitis C Cohort Study (SCCS)Open Forum Infectious Diseases
accessLevelPublic
2020 327 150
Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial SettingClinical Infectious Diseases
accessLevelPublic
2019 379 277
Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis c patientsPLOS ONE
accessLevelPublic
2019 389 134
Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent mannerInternational Journal of Molecular Sciences
accessLevelPublic
2019 483 196
A review on hepatitis D: from virology to new therapiesJournal of Advanced Research
accessLevelPublic
2019 413 235
Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort StudyPLOS ONE
accessLevelPublic
2019 428 195
Devil hepatitis D: an orphan disease or largely underdiagnosed?Gut
accessLevelRestricted
2019 360 0
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trialsLiver International
accessLevelPublic
2019 265 64
Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing?Clinical Infectious Diseases
accessLevelPublic
2019 491 140
Programme national de lutte contre le VIH, les IST et l'hépatite virale: unir les forces contre le VIH et les hépatites viralesBulletin des médecins suisses
accessLevelPublic
2019 425 171
Identification of an endoglin variant associated with HCV-related liver fibrosis progression by next-generation sequencingFrontiers in Genetics
accessLevelPublic
2019 296 111
Natural history of hepatic and extrahepatic hepatitis C virus diseases and impact of interferon-free HCV therapyCold Spring Harbor Perspectives in Medicine
accessLevelRestricted
2019 283 2
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidatesClinical Gastroenterology and Hepatology
accessLevelRestricted
2019 356 0
Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a proteinLiver International
accessLevelPublic
2019 423 256
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysisJournal of Viral Hepatitis
accessLevelPublic
2019 290 114
Nonalcoholic fatty liver disease burdenSwiss Medical Weekly
accessLevelPublic
2019 287 132
Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regionsSwiss Medical Weekly
accessLevelPublic
2019 397 266
Tolerogenic propreties of liver macrophages in non-alcoholic steatohepatitisLiver International
accessLevelPublic
2019 420 442
Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in SwitzerlandSwiss Medical Weekly
accessLevelPublic
2019 1,085 282
Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysisJournal of Viral Hepatitis
accessLevelRestricted
2019 407 1
The heavy burden of hepatitis D in UzbekistanLiver International
accessLevelRestricted
2019 294 0
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyThe Lancet Gastroenterology & Hepatology
accessLevelRestricted
2018 322 0
Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prisonJournal of Global Health
accessLevelPublic
2018 386 183
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)Hepatology
accessLevelPublic
2018 450 490
Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver diseaseWorld Journal of Hepatology
accessLevelPublic
2018 413 274
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030Journal of Hepatology
accessLevelPublic
2018 971 374
Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinomaHepatology
accessLevelRestricted
2018 482 0
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countriesAntiviral Research
accessLevelRestricted
2018 406 0
A buyers' club to improve access to hepatitis C treatment for vulnerable populationsSwiss Medical Weekly
accessLevelPublic
2018 1,175 407
EASL Clinical Practice Guidelines on hepatitis E virus infectionJournal of Hepatology
accessLevelRestricted
2018 371 2
The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic diseaseJournal of Viral Hepatitis
accessLevelPublic
2018 292 155
Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin AmericaJournal of Tropical Medicine
accessLevelPublic
2018 699 255
Expert opinion on the management of renal manifestations of chronic HCV infectionAntiviral Therapy
accessLevelRestricted
2018 332 0
EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology
accessLevelRestricted
2018 324 0
Combler les lacunes dans les tests de dépistage de l'hépatiteBulletin des médecins suisses
accessLevelPublic
2018 434 161
Expanded benefits of curing the extrahepatic manifestations of HCV infectionGut
accessLevelPublic
2018 282 205
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosisHepatology
accessLevelRestricted
2018 265 0
Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policiesJournal of Hepatology
accessLevelRestricted
2018 462 1
Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?PLOS ONE
accessLevelPublic
2018 380 179
Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic reviewJournal of Viral Hepatitis
accessLevelRestricted
2018 505 0
Cardiovascular Manifestations of Hepatitis C VirusClinics in Liver Disease
accessLevelRestricted
2017 460 2
Hépatite B : nouvelles recommandations de prise en chargeRevue médicale suisse
accessLevelRestricted
2017 529 2
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling studyThe Lancet Gastroenterology & Hepatology
accessLevelRestricted
2017 295 0
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A reviewJournal of Advanced Research
accessLevelPublic
2017 493 322
Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from overSwiss Medical Weekly
accessLevelPublic
2017 404 162
Estimating HCV disease burden-volume 4 (editorial)Journal of Viral Hepatitis
accessLevelRestricted
2017 363 0
Extrahepatic manifestations in hepatitis C virus infectionJournal of Advanced Research
accessLevelPublic
2017 409 112
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030Swiss Medical Weekly
accessLevelPublic
2017 911 227
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling studyThe Lancet Gastroenterology & Hepatology
accessLevelRestricted
2017 309 0
Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistanceNature Communications
accessLevelPublic
2017 1,506 393
The impact of hepatitis C virus outside the liver: Evidence from AsiaLiver international
accessLevelRestricted
2017 413 1
Editor's noteLiver International
accessLevelRestricted
2017 188 0
Hépatites B et C : nouveaux traitementsRevue médicale suisse
accessLevelRestricted
2017 384 0
Health-related quality of life in chronic HCV-infected patients switching to pegylated-interferon-free regimens (ARNS CO20 CUPIC cohort study and SIRIUS trial)The Patient - Patient-Centered Outcomes Research
accessLevelRestricted
2017 248 1
A Systematic Review and Meta-Analysis of HCV ClearanceLiver international
accessLevelRestricted
2017 530 1
Nucleic acid polymers: much-needed hope for hepatitis D?The Lancet Gastroenterology & Hepatology
accessLevelRestricted
2017 357 1
BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver diseaseOncotarget
accessLevelRestricted
2017 533 2
Trends in hepatitis C-related mortality in SwitzerlandJournal of Hepatology
accessLevelPublic
2017 1,175 626
The negative impact of HBV/HCV coinfection on cirrhosis and its consequencesAlimentary Pharmacology and Therapeutics
accessLevelRestricted
2017 440 0
Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related ProteinPloS one
accessLevelPublic
2016 1,142 214
Effect of quercetin on hepatitis C virus life cycle: from viral to host targetsScientific Reports
accessLevelPublic
2016 421 128
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genesGut
accessLevelRestricted
2016 343 1
Quels espoirs pour l'hépatite delta ?Revue médicale suisse
accessLevelRestricted
2016 403 1
Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening RecommendationsPloS one
accessLevelPublic
2016 584 514
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirinJournal of hepatology
accessLevelRestricted
2016 490 3
The hepatitis delta virus: Replication and pathogenesisJournal of hepatology
accessLevelRestricted
2016 524 2
Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver diseaseWorld journal of gastroenterology
accessLevelRestricted
2016 572 6
Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric SurgeryClinical gastroenterology and hepatology
accessLevelRestricted
2016 501 0
A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantationLiver international
accessLevelRestricted
2016 522 1
Drug Pricing Evolution in Hepatitis CPloS one
accessLevelPublic
2016 1,328 591
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genesNature communications
accessLevelPublic
2015 545 148
ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipientTransplant international
accessLevelRestricted
2015 629 1
Modeling the Health and Economic Burden of Hepatitis C Virus in SwitzerlandPloS one
accessLevelPublic
2015 579 1,313
Birth cohort distribution and screening for viraemic hepatitis C virus infections in SwitzerlandSchweizerische medizinische Wochenschrift
accessLevelPublic
2015 576 212
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patientsJournal of Viral Hepatitis
accessLevelRestricted
2015 281 0
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis CPloS one
accessLevelPublic
2015 671 306
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearanceHepatology
accessLevelRestricted
2015 319 0
Are statins a remedy for all seasons?Journal of hepatology
accessLevelPublic
2015 603 230
Extrahepatic morbidity and mortality of chronic hepatitis CGastroenterology
accessLevelRestricted
2015 445 0
The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012Virology
accessLevelRestricted
2015 497 0
Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC studyPLOS ONE
accessLevelPublic
2015 257 147
Repenser la politique de remboursement des agents antiviraux directs contre l'hépatite C chroniqueRevue médicale suisse
accessLevelRestricted
2015 502 1
Extrahepatic manifestations of HCVMinerva gastroenterologica e dietologica
2015 516 0
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infectionAlimentary pharmacology & therapeutics
accessLevelRestricted
2014 597 0
Is genotype 3 of the hepatitis C virus the new villain ?Hepatology
accessLevelRestricted
2014 308 0
Clinical significance of the CCR5delta32 allele in hepatitis CPloS one
accessLevelPublic
2014 525 203
HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesisPloS one
accessLevelPublic
2014 561 216
Curbing hepatitis C virus spread in EgyptThe Lancet. Global health
accessLevelRestricted
2014 540 0
Historical epidemiology of hepatitis C virus (HCV) in selected countriesJournal of viral hepatitis
accessLevelRestricted
2014 594 1
Hepatitis D virus coinfection and superinfectionCold Spring Harbor perspectives in medicine
2014 456 0
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of viral hepatitis
accessLevelRestricted
2014 564 1
The impact of obesity and metabolic syndrome on chronic hepatitis CClinics in liver disease
2014 529 0
Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3eJournal of general virology
accessLevelRestricted
2014 519 0
EASL Clinical Practice Guidelines: management of hepatitis C virus infectionJournal of hepatology
accessLevelRestricted
2014 579 0
Transplantation cellulaire : traitements actuels et perspectives d'avenirRevue médicale suisse
accessLevelRestricted
2014 872 14
Does telaprevir possess a direct antidiabetic effect?Liver international
accessLevelRestricted
2014 582 0
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass IndexPLOS genetics
accessLevelPublic
2014 703 1,223
Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseasesJournal of hepatology
accessLevelPublic
2014 549 253
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patientsLiver international
accessLevelRestricted
2014 557 0
Epidemiology of hepatitis C in EuropeDigestive and Liver Disease
accessLevelPublic
2014 548 238
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genesNature communications
accessLevelPublic
2014 594 1,191
Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infectionReviews on recent clinical trials
2014 536 0
Strategies to manage hepatitis C virus (HCV) disease burdenJournal of viral hepatitis
accessLevelRestricted
2014 562 1
Hepatitis C in 2013: HCV causes systemic disorders that can be curedNature reviews. Gastroenterology & hepatology
accessLevelRestricted
2014 588 2
Morbidité et mortalité extrahépatiques associées à l'infection par le virus de l'hépatite CRevue médicale suisse
accessLevelRestricted
2014 527 1
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma developmentPloS one
accessLevelPublic
2013 650 605
PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolismJournal of hepatology
accessLevelRestricted
2013 667 2
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinomaJournal of hepatology
accessLevelRestricted
2013 613 0
Role of seipin in lipid droplet morphology and hepatitis C virus life cycleJournal of general virology
accessLevelRestricted
2013 622 1
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance predictionThe Journal of experimental medicine
accessLevelRestricted
2013 544 0
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionPloS one
accessLevelPublic
2013 597 202
STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in Rosiglitazone-treated miceScientific reports
accessLevelRestricted
2013 668 3
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trialHepatology
accessLevelRestricted
2013 556 0
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis CLiver international
accessLevelRestricted
2013 621 0
Réactivation de l'hépatite B au cours de l'immunosuppressionRevue médicale suisse
accessLevelRestricted
2013 564 0
Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infectionSchweizerische medizinische Wochenschrift
accessLevelRestricted
2013 631 0
Statins may protect against hepatocellular carcinoma development in patients infected with hepatitis C virus, but what are the mechanisms?Journal of clinical oncology
accessLevelRestricted
2013 587 0
IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4Journal of viral hepatitis
accessLevelRestricted
2013 598 0
IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5Gut
accessLevelRestricted
2012 561 0
Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapyHepatology
accessLevelRestricted
2012 563 0
HCV infection and metabolic syndrome: which is the chicken and which is the egg?Gastroenterology
accessLevelRestricted
2012 429 0
The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patientsAntiviral therapy
accessLevelRestricted
2012 644 1
Steatosis and insulin resistance in response to treatment of chronic hepatitis CJournal of viral hepatitis
accessLevelRestricted
2012 573 0
Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II studyHepatology
accessLevelRestricted
2012 576 0
A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis CPloS one
accessLevelPublic
2012 705 358
Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis CJournal of viral hepatitis
accessLevelRestricted
2012 592 0
Nonalcoholic fatty liver disease in lean individuals in the United StatesMedicine
accessLevelRestricted
2012 528 0
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypesHepatology
accessLevelRestricted
2012 626 0
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infectionGastroenterology
accessLevelRestricted
2012 590 0
The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirinJournal of viral hepatitis
accessLevelRestricted
2012 575 0
The interaction of metabolic factors with HCV infection: does it matter?Journal of hepatology
accessLevelRestricted
2012 568 0
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndromeDigestive and Liver Disease
accessLevelRestricted
2012 523 0
Défis de la co-infection par le virus de l'hépatite C et le VIHRevue médicale suisse
accessLevelRestricted
2012 562 0
Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infectionJournal of viral hepatitis
accessLevelRestricted
2012 631 0
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinomaSchweizerische medizinische Wochenschrift
accessLevelRestricted
2012 525 0
Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesityInternational journal of obesity
accessLevelRestricted
2012 696 5
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled studyBMC gastroenterology
accessLevelPublic
2012 603 166
The global health burden of hepatitis C virus infectionLiver international
accessLevelRestricted
2011 512 0
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis CJournal of hepatology
accessLevelRestricted
2011 562 0
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US dataLiver international
accessLevelRestricted
2011 593 0
Trends and projections of hepatitis C virus epidemiology in Latin AmericaLiver international
accessLevelRestricted
2011 608 0
Mechanisms of hepatitis C virus-related insulin resistanceClinics and research in hepatology and gastroenterology
accessLevelRestricted
2011 530 0
IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis CAlimentary Pharmacology and Therapeutics
accessLevelRestricted
2011 143 0
Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: comparison between different genotypes and core protein sequence analysisJournal of medical virology
accessLevelRestricted
2011 692 0
Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosisJournal of hepatology
accessLevelRestricted
2011 554 1
Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid dropletsHepatology
accessLevelRestricted
2011 575 0
Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysisJournal of viral hepatitis
accessLevelRestricted
2011 536 0
Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infectionsJournal of hepatology
accessLevelRestricted
2011 617 0
Management of hepatitis C virus (HCV) infection in drug substitution programsSchweizerische medizinische Wochenschrift
accessLevelPublic
2011 604 473
A systematic review of hepatitis C virus epidemiology in Asia, Australia and EgyptLiver international
accessLevelRestricted
2011 1,088 0
Management of chronic hepatitis B: an updateSchweizerische medizinische Wochenschrift
accessLevelRestricted
2011 552 0
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphismsPloS one
accessLevelPublic
2011 585 278
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyPLoS medicine
accessLevelPublic
2011 638 219
Hépatite C chronique : traitement actuel et perspectivesRevue médicale suisse
accessLevelRestricted
2011 474 1
Nouveaux traitements de l'hépatite C : quelles cibles, quel calendrier?Revue médicale suisse
accessLevelRestricted
2011 495 0
Hepatitis D virus: an updateLiver international
accessLevelRestricted
2011 597 0
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patientsLiver international
accessLevelRestricted
2011 597 0
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelLiver international
accessLevelRestricted
2011 605 0
High-density EMG E-textile systems for the control of active prosthesesConference proceedings
2010 577 0
Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis CJournal of viral hepatitis
accessLevelRestricted
2010 543 1
Impact of international consensus guidelines on antiviral therapy of chronic hepatitis C patients in SwitzerlandSchweizerische medizinische Wochenschrift
accessLevelPublic
2010 590 106
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CHepatology
accessLevelRestricted
2010 512 0
Multimodal BCI-mediated FES suppression of pathological tremorConference proceedings
2010 635 0
Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infectionClinical gastroenterology and hepatology
2010 514 0
The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8Journal of hepatology
accessLevelRestricted
2010 637 2
Abnormalities of lipid metabolism in hepatitis C virus infectionGut
accessLevelRestricted
2010 535 0
Cause-effect relationship between the hepatitis C virus and insulin resistance at the time of direct antiviral therapyGut
accessLevelRestricted
2010 485 0
Hepatitis C virus-induced steatosis: an overviewDigestive diseases
accessLevelRestricted
2010 560 0
The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physiciansSchweizerische medizinische Wochenschrift
2010 485 0
Hepatitis E virus: a zoonosis adapting to humansThe journal of antimicrobial chemotherapy
accessLevelRestricted
2010 510 1
Hépatite D:oubliée mais pas disparueRevue médicale suisse
2010 512 0
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison studySchweizerische medizinische Wochenschrift
2010 647 0
Experimental analysis of accuracy in the identification of motor unit spike trains from high-density surface EMGIEEE transactions on neural systems and rehabilitation engineering
2010 624 0
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association studyGastroenterology
accessLevelRestricted
2010 843 0
Adverse effects of drugs in the treatment of viral hepatitisBaillière's best practice & research. Clinical gastroenterology
accessLevelRestricted
2010 527 0
Hepatitis delta virus inhibits alpha interferon signalingHepatology
accessLevelRestricted
2009 546 0
Hepatitis C virus and type 2 diabetesWorld journal of gastroenterology
accessLevelRestricted
2009 522 0
Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic dataLiver international
accessLevelRestricted
2009 520 0
Hepatitis C virus infection: molecular pathways to steatosis, insulin resistance and oxidative stressViruses
accessLevelPublic
2009 556 225
Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort StudyJournal of viral hepatitis
accessLevelRestricted
2009 524 0
Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis CJournal of hepatology
accessLevelRestricted
2009 612 0
Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis CJournal of Viral Hepatitis
accessLevelRestricted
2009 158 0
Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistancePPAR research
accessLevelRestricted
2009 535 0
Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantationTransplant infectious disease
accessLevelRestricted
2009 498 0
Chronic hepatitis E in the immunosuppressed: a new source of trouble?Journal of hepatology
accessLevelRestricted
2009 551 0
Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteinsLiver international
accessLevelRestricted
2009 610 0
Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answersJournal of hepatology
accessLevelRestricted
2009 525 0
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3Journal of hepatology
accessLevelRestricted
2008 601 0
Hepatitis C virus and glucose and lipid metabolismDiabetes & metabolism
accessLevelRestricted
2008 580 0
Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis CJournal of hepatology
accessLevelRestricted
2008 601 0
Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytesHepatology
accessLevelRestricted
2008 645 0
Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis CLiver international
accessLevelRestricted
2008 544 0
Host- rather than virus-related factors reduce health-related quality of life in hepatitis C virus infectionGut
accessLevelRestricted
2008 505 0
Steatosis in chronic hepatitis C: friend or foe?Liver international
accessLevelRestricted
2008 524 0
Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patientsJournal of viral hepatitis
accessLevelRestricted
2008 610 0
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapyJournal of hepatology
accessLevelRestricted
2008 586 0
Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirinJournal of hepatology
accessLevelRestricted
2008 595 0
The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanismsHepatology
accessLevelRestricted
2007 450 0
Hepatitis C virus: the viral way to fatty liverJournal of Hepatology
accessLevelRestricted
2007 148 0
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantationTransplant international
accessLevelRestricted
2004 753 0
Hepatocellular adenoma and polycystic ovary syndromeLiver international
accessLevelRestricted
2003 618 0
Lack of evidence for ribavirin-induced bone lossHepatology
accessLevelRestricted
2002 583 0
Immunological and virological effects of ribavirin in hepatitis C after liver transplantationTransplantation
accessLevelRestricted
2002 583 0
The intrahepatic T helper cytokine profile does not predict the response to alpha-interferon in chronic hepatitis CJournal of hepatology
accessLevelRestricted
2001 522 0
Are there any subgenomic forms of hepatitis C virus RNA in the liver?Digestive and Liver Disease
accessLevelRestricted
2001 581 0
Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferonJournal of hepatology
accessLevelRestricted
2001 530 0
Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesisAntiviral research
accessLevelRestricted
2001 542 0
Nosocomial outbreak of multiple bloodborne viral infectionsThe Journal of infectious diseases
accessLevelPublic
2001 585 230
A novel hepatitis C virus (HCV) subtype from Somalia and its classification into HCV clade 3Journal of general virology
accessLevelRestricted
2000 634 0
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3Journal of hepatology
accessLevelRestricted
2000 661 1
Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistanceScience
accessLevelRestricted
2000 596 0
Primary hepatic diffuse large B-cell lymphoma in a patient with chronic hepatitis CThe American journal of surgical pathology
accessLevelRestricted
1999 574 0
Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation modelJournal of hepatology
accessLevelRestricted
1998 530 0
Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIVThe Journal of infectious diseases
accessLevelRestricted
1998 576 0
Hepatitis G virus infection among liver graft recipients: anatomoclinical correlationsDigestive diseases and sciences
accessLevelRestricted
1998 567 0
IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantationJournal of medical virology
accessLevelRestricted
1998 784 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack